🇺🇸 FDA
Pipeline program

Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion

R3918-PNH-2021

Phase 3 small_molecule active

Quick answer

Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion for Paroxysmal nocturnal haemoglobinuria (PNH) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Paroxysmal nocturnal haemoglobinuria (PNH)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials